Skip to content
CNS Clinical Research

Dallas, Texas

CNS clinical trials in Dallas, TX

66 CNS studies are recruiting participants at sites in Dallas as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.

Call (888) 520-7418
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Dallas at a glance

  • 66 studies are recruiting at a site in Dallas.
  • By phase: Early Phase 1 (1), Phase 1 (1), Phase 1/2 (3), Phase 2 (8), Phase 3 (24), Phase 4 (4), No phase (15), Observational (10). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (39), university, hospital or other (25), government (2).
  • By research area: Depression (21), Parkinson's Disease (12), Migraine (11), Multiple Sclerosis (9), Epilepsy (7), Schizophrenia (4), ADHD (1), Bipolar Disorder (1).
  • Most recent update to one of these records: November 13, 2026.

Depression studies recruiting in Dallas

Basic details from each study's public record (the 30 most recently updated of 66). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Seaport Therapeutics
    Study site
    Seaport Investigator Site
    Registry record
    NCT07065240 · updated
  2. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    LivaNova
    Study site
    University of Texas Southwestern
    Registry record
    NCT03887715 · updated
  3. A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Future Search Trials of Dallas
    Registry record
    NCT07573176 · updated
  4. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT06966401 · updated
  5. A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tonix Pharmaceuticals, Inc.
    Registry record
    NCT07621237 · updated
  6. ALTO-207 in Adults With Treatment-resistant Depression (TRD)

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT07553637 · updated
  7. Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

    • No phase
    • Ages 22 to 70
    • All sexes
    Sponsor
    Abbott Medical Devices
    Study site
    University of Texas Southwestern Medical Center at Dallas
    Registry record
    NCT06423430 · updated
  8. ALTO-100 in Bipolar Disorder With Depression (BD-D)

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT06656416 · updated
  9. Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07484217 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Dallas, TX on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Dallas

  1. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - DFW ( Site 8007)
    Registry record
    NCT06841354 · updated
  2. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Texas Oncology - DFW ( Site 8009) · UT Southwestern ( Site 0092)
    Registry record
    NCT06966700 · updated
  3. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Texas Oncology - DFW ( Site 8103) · UT Southwestern Medical Center ( Site 0190)
    Registry record
    NCT06623422 · updated
  4. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Texas Neurology PA
    Registry record
    NCT07174310 · updated
  5. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    • Phase 2
    • Ages 40 to 80
    • All sexes
    Sponsor
    Neuron23 Inc.
    Study site
    Neurology Consultants of Dallas PA
    Registry record
    NCT06680830 · updated
  6. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Parkland Health and Hospital System ( Site 0069) · Texas Oncology-Dallas Presbyterian Hospital ( Site 8000) · UT Southwestern Medical Center ( Site 0050)
    Registry record
    NCT06312176 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Dallas, TX on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Dallas

  1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT03816345 · updated
  2. A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT06433752 · updated
  3. Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

    • Phase 3
    • Ages 40 to 70
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Univ of Texas Southwest Med Center
    Registry record
    NCT06846281 · updated
  4. Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

    • Phase 3
    • Ages 18 to 55
    • All sexes
    Sponsor
    National Institute of Allergy and Infectious Diseases (NIAID)
    Study site
    University of Texas Southwestern Medical Center: Division of Multiple Sclerosis and Neuroimmunology
    Registry record
    NCT04047628 · updated
  5. A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Carum Research
    Registry record
    NCT07225504 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Dallas, TX on ClinicalTrials.gov.

Epilepsy studies recruiting in Dallas

  1. Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Neurona Therapeutics
    Study site
    UT Southwestern Medical Center
    Registry record
    NCT05135091 · updated
  2. Diagnosing Epilepsy To EffeCT Change

    • No phase
    • Ages 18 to 75
    • All sexes
    Sponsor
    Epiminder America, Inc.
    Study site
    UT Southwestern Medical Center
    Registry record
    NCT07110337 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Dallas, TX on ClinicalTrials.gov.

Migraine studies recruiting in Dallas

  1. Study of EVO756 in Adults With Migraine

    • Phase 2
    • Ages 18 to 64
    • All sexes
    Sponsor
    Evommune, Inc.
    Study site
    FutureSearch Trials of Dallas
    Registry record
    NCT07616128 · updated
  2. A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Velocity Clinical Research, Dallas
    Registry record
    NCT07816367 · updated
  3. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    FutureSearch Trials of Dallas, LP
    Registry record
    NCT07645924 · updated
  4. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    FutureSearch Trials of Dallas, LP
    Registry record
    NCT07674654 · updated
  5. Randomized Study in Children and Adolescents With Migraine: Acute Treatment

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    FutureSearch Trials of Dallas, LLC
    Registry record
    NCT04649242 · updated
  6. Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    Alina Clinical Trials, LLC.
    Registry record
    NCT05156398 · updated
  7. A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

    • Phase 4
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    FutureSearch Trials of Dallas
    Registry record
    NCT07609914 · updated
  8. A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    FutureSearch Trials of Dallas
    Registry record
    NCT07729462 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Dallas, TX on ClinicalTrials.gov.

Ask about studies near Dallas

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Texas

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 520-7418

or send a short form

How should we reach you?

Call